The biotechnology company Novavax will soon begin the second phase of human testing for its COVID-19 vaccine.
The so-called phase 2b clinical trial will include a group of 2,665 healthy adults in South Africa, as well as a group of 240 adults with HIV who are considered medically stable but whose immune responses may differ from individuals without HIV, according to a statement released by Novavax on Aug. 17. HIV advocacy groups have pushed for people with HIV to be included in clinical trials for COVID-19 vaccines, as companies like Moderna and Pfizer initially said they would exclude volunteers with the infection, Science Magazine reported.
{iframe}https://www.livescience.com/novavax-covid19-vaccine-update.html?utm_source=Selligent&utm_medium=email&utm_campaign=22090&utm_content=20200817_Coronavirus_Infographic+&utm_term=3325322&m_i=ql0q_FwvnitTkZHBySNGqgMs4e19EsNlZxvRsGuQqGwifm_LKXaOHvJGRoKyGM6QVTx6QY2UeEJqLhhldKeFM33P7JrvMt{/iframe}